Journal
AAPS JOURNAL
Volume 11, Issue 3, Pages 432-434Publisher
SPRINGER
DOI: 10.1208/s12248-009-9120-5
Keywords
engineered Fc; FcRn; IgG; inhibitors; monoclonal antibody; peptide
Categories
Ask authors/readers for more resources
The neonatal Fc receptor, FcRn, is responsible for controlling the half-life of IgG antibodies. As a result, inhibitors of FcRn have been investigated as a possible way to modulate IgG half-lives. Such inhibitors could have possible applications in reducing autoantibody levels in autoimmune disease states. To date, monoclonal antibodies, engineered Fc domains, and short peptides have been reported to inhibit FcRn function and modulate IgG half-lives in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available